ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the company has revised its 2018 financial guidance upwards based on an expected strong end to the year which further builds on the momentum established during the first nine months:
Performance in Q4 has so far been better than expected, mainly because of a positive development in Europe. SLIT-tablet sales grow as expected, while sales of SCIT, SLIT-drops and Jext® are exceeding expectations with improved product availability and robustness in product supply enabling ALK to meet increased demand. The increased operating profit (EBITDA) primarily reflects this higher than expected revenue. Free cash flow is primarily impacted by the higher EBITDA.
ALK will publish its Q4 performance in connection with the Annual Report on 7 February 2019.
For further information please contact:
Carsten Hellmann, President & CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014
This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,300 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.